"N Engl J Med"[journal] 检索结果

141. Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer.

作者: Neal D Shore.;Murilo de Almeida Luz.;Ugo De Giorgi.;Martin Gleave.;Geoffrey T Gotto.;Christopher M Pieczonka.;Gabriel P Haas.;Choung-Soo Kim.;Miguel Ramirez-Backhaus.;Antti Rannikko.;Matko Kalac.;Swetha Sridharan.;Matt Rosales.;Yiyun Tang.;Ronald F Tutrone.;Balaji Venugopal.;Arnauld Villers.;Henry H Woo.;Fong Wang.;Stephen J Freedland.
来源: N Engl J Med. 2025年

In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis-free survival than leuprolide alone among patients with biochemically recurrent prostate cancer. The final analysis of overall survival has not been reported.

142. Nivolumab for Resected Stage III or IV Melanoma at 9 Years.

作者: Paolo A Ascierto.;Michele Del Vecchio.;Barbara Merelli.;Helen Gogas.;Ana M Arance.;Stéphane Dalle.;Charles Lance Cowey.;Michael Schenker.;Caroline Gaudy-Marqueste.;Jacopo Pigozzo.;Iván Márquez-Rodas.;Marcus O Butler.;Anna Maria Di Giacomo.;Oleg Gligich.;Luis De La Cruz-Merino.;Petr Arenberger.;Victoria Atkinson.;Paul Nathan.;Andrew Hill.;Michael Millward.;Leslie A Fecher.;Nikhil I Khushalani.;Paola Queirolo.;Raheela Soomro.;Dhanrajsinh Rathod.;Margarita Askelson.;Melanie Pe Benito.;Devanand Joseph.;James Larkin.
来源: N Engl J Med. 2025年

In the CheckMate 238 trial, patients with resected stage IIIB-C or stage IV melanoma who were treated with nivolumab had longer recurrence-free survival than those who received ipilimumab. Data were needed on longer-term survival.

143. Thirty Years of Hydroxyurea for Sickle Cell Anemia - Scientific Progress, Global Health Gaps.

作者: Enrico Costa.;Russell Ware.;Leon Tshilolo.;Lucio Luzzatto.
来源: N Engl J Med. 2025年393卷16期1556-1559页

144. Fetal Personhood and Reproductive Criminalization - Implications for Patients, Clinicians, and Public Health.

作者: Taylor Riley.;Asha Hassan.
来源: N Engl J Med. 2025年393卷16期1559-1561页

145. Involving Palliative Care to Improve Outcomes in Sickle Cell Disease.

作者: Eberechi Nwogu-Onyemkpa.;Griffin Collins.;Mgbechi Erondu.;Erica C Kaye.
来源: N Engl J Med. 2025年393卷16期1553-1556页

146. Living in the Present Tense.

作者: James A Feinstein.
来源: N Engl J Med. 2025年393卷16期1561-1563页

147. Thoracic Ectopia Cordis.

作者: Zeljko Duric.;Hrvoje Gasparovic.
来源: N Engl J Med. 2025年393卷16期e26页

148. Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC.

作者: Pasi A Jänne.;David Planchard.;Kunihiko Kobayashi.;James Chih-Hsin Yang.;Ying Liu.;Natalia Valdiviezo.;Tae Min Kim.;Liyan Jiang.;Hiroshi Kagamu.;Noriko Yanagitani.;Jialei Wang.;Bivas Biswas.;Artem Poltoratskiy.;Yeni Neron.;Carlos Rojas.;Leona Koubkova.;Carles Escriu.;Doreen A Ezeife.;Helen Mann.;Elena Armenteros-Monterroso.;Yuri Rukazenkov.;Chee Khoon Lee.; .
来源: N Engl J Med. 2025年

The primary analysis of this trial showed that first-line treatment with osimertinib plus chemotherapy with a platinum-based agent and pemetrexed led to significantly longer progression-free survival than osimertinib monotherapy among patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC). Results from the planned final analysis of overall survival are needed.

149. Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.

作者: Xiuning Le.;Tae Min Kim.;Herbert H Loong.;Arsela Prelaj.;Boon Cher Goh.;Lin Li.;Yong Fang.;Shun Lu.;Xiaorong Dong.;Lin Wu.;Yuki Shinno.;Gennaro Daniele.;Tsung-Ying Yang.;Hye Ryun Kim.;Gerrina Ruiter.;Jun Zhao.;Silvia Novello.;Liyun Miao.;Pasi A Jänne.;Koichi Goto.;Dominik Rüttinger.;Tine Descamps.;Jan Christoph Brase.;Weichao Bao.;Rui Li.;Nicoletta Brega.;Paolo Grassi.;Nicolas Girard.;Daniel Shao-Weng Tan.; .
来源: N Engl J Med. 2025年393卷18期1819-1832页

HER2 gene mutations occur in 2 to 4% of patients with non-small-cell lung cancer (NSCLC). Sevabertinib is an oral, reversible tyrosine kinase inhibitor that has shown anti-HER2 activity in preclinical models.

150. Is a Long-Simmering Crisis Boiling Over? U.S. Primary Care Today.

作者: Lisa Rosenbaum.
来源: N Engl J Med. 2025年393卷15期1537-1541页

151. More about the Phase 2a Study of Baxdrostat in Primary Aldosteronism. Reply.

作者: Adina F Turcu.;Mason W Freeman.;Morris J Brown.
来源: N Engl J Med. 2025年393卷15期1550-1552页

152. More about the Phase 2a Study of Baxdrostat in Primary Aldosteronism.

作者: Tobias Carling.;Ute I Scholl.
来源: N Engl J Med. 2025年393卷15期1550页

153. Competency-Based Medical Education at the Front Lines of Patient Care. Reply.

作者: Dawn Cooper.;Eric S Holmboe.
来源: N Engl J Med. 2025年393卷15期1549-1550页

154. Competency-Based Medical Education at the Front Lines of Patient Care.

作者: Kévin Yauy.;Camille Roubille.
来源: N Engl J Med. 2025年393卷15期1548-1549页

155. Competency-Based Medical Education at the Front Lines of Patient Care.

作者: George W Meyer.
来源: N Engl J Med. 2025年393卷15期1548页

156. Competency-Based Medical Education at the Front Lines of Patient Care.

作者: Alexander A Iyer.;Nicole M Dubosh.;Richard M Schwartzstein.
来源: N Engl J Med. 2025年393卷15期1548页

157. BCMA T-Cell Engager Therapy in Patients with Refractory Autoimmune Disease.

作者: Laura Bucci.;Sebastian Böltz.;Melanie Hagen.;Carlo Tur.;Danae-Mona Nöthling.;Tobias Rothe.;Andreas Wirsching.;Janina Auth.;Jochen Wacker.;Markus Eckstein.;Stefano Alivernini.;Aline Bozec.;Christina Bergmann.;Maria-Antonietta D'Agostino.;Luis Munoz.;Jürgen Rech.;Lars Kihm.;Maria Gabriella Raimondo.;Georg Schett.;Ricardo Grieshaber-Bouyer.
来源: N Engl J Med. 2025年393卷15期1544-1547页

158. Sentinel Lymphadenectomy for Early-Stage Cervical Cancer - the New Standard?

作者: Kristin Bixel.
来源: N Engl J Med. 2025年393卷15期1534-1536页

159. Case 29-2025: A 43-Year-Old Woman with Depression, Suicidal Ideation, and Fever.

作者: Michael S Abers.;Robert J Lawson.;Sandra B Nelson.;Melanie C Kwan.
来源: N Engl J Med. 2025年393卷15期1522-1531页

160. Stercoral Colitis.

作者: Aleksandra Bajer.;Erica Levine.
来源: N Engl J Med. 2025年393卷15期e23页

结果排序

文献格式

出版时间

出版类型

出版语言